Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10506MR)

This product GTTS-WQ10506MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10506MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11514MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ9250MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ15392MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRU-016
GTTS-WQ3053MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13619MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ15512MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ8244MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW